Flutterby™! : CBD 2018-12-26 16:56:05.827364+01

CBD

2018-12-26 16:56:05.827364+01 by Dan Lyke 0 comments

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

RESULTS: After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms (PANSS: treatment difference=-1.4, 95% CI=-2.5, -0.2) and were more likely to have been rated as improved (CGI-I: treatment difference=-0.5, 95% CI=-0.8, -0.1) and as not severely unwell (CGI-S: treatment difference=-0.3, 95% CI=-0.5, 0.0) by the treating clinician. Patients who received CBD also showed greater improvements that fell short of statistical significance in cognitive performance (BACS: treatment difference=1.31, 95% CI=-0.10, 2.72) and in overall functioning (GAF: treatment difference=3.0, 95% CI=-0.4, 6.4). CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups.

Comment policy

We will not edit your comments. However, we may delete your comments, or cause them to be hidden behind another link, if we feel they detract from the conversation. Commercial plugs are fine, if they are relevant to the conversation, and if you don't try to pretend to be a consumer. Annoying endorsements will be deleted if you're lucky, if you're not a whole bunch of people smarter and more articulate than you will ridicule you, and we will leave such ridicule in place.

Flutterby™ is a trademark claimed by